lestaurtinib has been researched along with pik 75 in 1 studies
| Studies (lestaurtinib) | Trials (lestaurtinib) | Recent Studies (post-2010) (lestaurtinib) | Studies (pik 75) | Trials (pik 75) | Recent Studies (post-2010) (pik 75) |
|---|---|---|---|---|---|
| 124 | 12 | 63 | 35 | 0 | 31 |
| Protein | Taxonomy | lestaurtinib (IC50) | pik 75 (IC50) |
|---|---|---|---|
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | Homo sapiens (human) | 0.91 | |
| Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta | Homo sapiens (human) | 0.2476 | |
| Cyclin-T1 | Homo sapiens (human) | 0.0014 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 0.0052 | |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | Homo sapiens (human) | 0.1256 | |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | Homo sapiens (human) | 0.2661 | |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | Homo sapiens (human) | 0.2476 | |
| Glycogen synthase kinase-3 beta | Homo sapiens (human) | 0.009 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 0.0014 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.34 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bharate, SB; Raghuvanshi, R | 1 |
1 other study(ies) available for lestaurtinib and pik 75
| Article | Year |
|---|---|
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |